Nurix Therapeutics, INC

Nurix Therapeutics announced a significant global collaboration with Roche for bexobrutideg, potentially worth up to $2.3 billion, alongside its second-quarter financial results which showed a net loss but a strong cash position bolstered by the expected upfront payment.

Nurix Therapeutics announced updated clinical data for bexobrutideg, a BTK degrader, showing high response rates and durable efficacy in chronic lymphocytic leukemia patients.

Nurix Therapeutics and Roche have entered into a global collaboration to co-develop and co-commercialize bexobrutideg, a BTK degrader, with potential total payments up to $2.3 billion.

Nurix Therapeutics stockholders re-elected three directors and ratified the appointment of its independent auditor.

Nurix Therapeutics announced its first quarter 2026 financial results, highlighting progress in its bexobrutinib program and a well-capitalized balance sheet.

Nurix Therapeutics, Inc. amended its equity distribution agreement to increase its at-the-market offering capacity to $413.65 million, providing additional funding flexibility.

Nurix Therapeutics filed its Form 10-Q for the quarter ended May 31, 2026, detailing significant operating expenses and a net loss, while highlighting ongoing clinical trials and strategic collaborations.

Nurix Therapeutics, Inc. reported a net loss of $87.2 million for the three months ended February 28, 2026, with collaboration revenue decreasing to $6.3 million.

Nurix Therapeutics reported increased net losses in Q3 2025 driven by accelerated R&D spending on its clinical pipeline, while securing significant license revenue from Sanofi.

Nurix Therapeutics, a clinical-stage biopharmaceutical company, reported a significant increase in total revenue driven by new license agreements, alongside a substantial rise in research and development expenses leading to increased net losses, while advancing its lead drug candidates and securing key regulatory designations.

Nurix Therapeutics reports its financial results for the quarter ended February 28, 2025, and provides an update on its clinical development programs and collaborations.

Nurix Therapeutics' third quarter 2024 results show a net loss of $48.9 million, with collaboration revenue of $12.5 million, and significant progress in clinical development.

Nurix Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $264.5 million for fiscal year 2025, while advancing its targeted protein degradation pipeline with key clinical milestones and strategic collaborations.

Nurix Therapeutics' 10-K filing highlights clinical progress, strategic plans for 2025, and financial collaborations aimed at advancing targeted protein degradation medicines.

Nurix Therapeutics has amended its collaboration agreement with Sanofi and filed its annual report on Form 10-K, detailing its financial position and clinical pipeline.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, Inc., sold 16,589 shares of common stock on August 3, 2026 for $23.05 per share.

Houte Hans Van, Chief Financial Officer of Nurix Therapeutics, Inc., sold 2,845 shares of common stock on July 30, 2026 for $23.38 per share.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, Inc., sold 3,847 shares of common stock on July 30, 2026 for $23.38 per share.

Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc., sold 3,847 shares of common stock on July 30, 2026 for $23.38 per share.

Nurix Therapeutics Chief Legal Officer Christine Ring executed a series of stock transactions on July 2, 2026, under a pre-established Rule 10b5-1 trading plan.

Gwenn Hansen, Chief Scientific Officer at Nurix Therapeutics, Inc., sold 5,394 shares of common stock on June 25, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Nurix Therapeutics reports significant progress in its oncology and inflammation & immunology pipelines, highlighted by pivotal trial advancements for bexobrutideg and a strengthened financial position.

Nurix Therapeutics has filed a definitive proxy statement with the SEC.

Nurix Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on May 19, 2025, highlighting the company's advancements in targeted protein degradation medicines and strategic goals for the upcoming year.

Nurix Therapeutics has filed a definitive proxy statement with the SEC.

Nurix Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on May 20, 2024, to vote on director elections, ratification of the accounting firm, and executive compensation.

Vanguard Capital Management has reported beneficial ownership of over 5.03% of Nurix Therapeutics Inc. common stock as of June 30, 2026.

Vestal Point Capital, LP and Ryan Wilder have filed a Schedule 13G reporting a 6.3% beneficial ownership stake in Nurix Therapeutics, Inc.

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 6,345,244 shares, representing 6.17% of Nurix Therapeutics, Inc.'s common stock as of March 31, 2026.

FMR LLC, through its affiliates, has reported beneficial ownership of 5.4% of Nurix Therapeutics Inc.'s common stock as of March 31, 2026.

Redmile Group has completed an internal reorganization of its holdings in Nurix Therapeutics, maintaining a 9.9% stake while shifting direct ownership to a new subsidiary.

The Vanguard Group has reported a 0% beneficial ownership in Nurix Therapeutics Inc. common stock following an internal realignment.